235 Walnut Street
Suite 6
Framingham, MA 01702
United States
617 431 2313
https://www.archtherapeutics.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 8
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Terrence W. Norchi M.D. | Co-Founder, Chairman, President & CEO | 450,5k | N/D | 1965 |
Mr. Michael S. Abrams | CFO & Treasurer | 325k | N/D | 1970 |
Dr. Rutledge Ellis-Behnke Ph.D. | Co-Founder & Scientific Advisor | N/D | N/D | N/D |
Mr. Shawn Carlson | Vice President of Sales | N/D | N/D | N/D |
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
L'ISS Governance QualityScore di Arch Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.